Table 1.

Characteristics of eligible studies considered in the report

Author_Year	Genetic variant	Patients included, n	Study design	Genotype analysis	Previous treatment	Study treatment	Response criteria
Zhang_2006 [22] (IMCL-0144)	EGF A61G	34	Retrospective†	PCR-RFLP	≥ 2 chemotherapy	C alone	WHO
Graziano-2008 [19]	EGF A61G	110	Prospective	PCR-RFLP	≥ 1 chemotherapy	C + I	RECIST
Lurje-2008 (IMCL-0144) [21]	EGF A61G	116	Retrospective†	PCR-RFLP	≥ 2 chemotherapy	C alone	WHO
Garm-2009 [18]	EGF A61G	71	Retrospective	Taq-PCR	≥ 1 chemotherapy	C + I	RECIST
Pander-2010 (CAIRO2) [23]	EGF A61G	120	Retrospective†	Taq-PCR	untreated	C + O	RECIST
Hu-2011 (multicenter) [20]	EGF A61G	118	Retrospective†	PCR-RFLP	RT	C + O	Dworak

C alone: cetuximab used as single agent; C + I: cetuximab used in combination with irinotecan; C + O: cetuximab used in combination with oxaliplatin; RECIST: Response Evaluation Criteria in Solid Tumors; PCR-RFLP: Polymerase Chain Reaction-Restriction Fragment Length Polymorphism.